OncoMatch/Clinical Trials/NCT06206096
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Is NCT06206096 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies oxaliplatin+capecitabine+bevacizumab+PD-1 antibody for colorectal cancer.
Treatment: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody — This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS mutation
KRAS/NRAS mutation
Required: NRAS mutation
KRAS/NRAS mutation
Required: MSH2 microsatellite stable
With BRAF mutation or MSI-H status
Excluded: BRAF mutation
With BRAF mutation or MSI-H status
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: VEGFR inhibitor
Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors
Cannot have received: immune checkpoint inhibitor
previous use of immune checkpoint inhibitors
Cannot have received: systemic anti-tumor treatments
Exception: within 4 weeks before enrollment
have received other systemic anti-tumor treatments, including chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy within 4 weeks before enrollment
Cannot have received: local anti-tumor therapy (hepatic artery interventional embolization, liver metastasis cryoablation, radiofrequency ablation)
Exception: within 4 weeks before enrollment
have received Local anti-tumor therapy such as hepatic artery interventional embolization, liver metastasis cryoablation or radiofrequency ablation within 4 weeks before enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5x10^9/L; Platelet count ≥100x10^9/L; Hemoglobin ≥9g/dL
Kidney function
Serum creatinine <1.5x ULN; Endogenous creatinine clearance rate ≥ 50ml / min
Liver function
Serum bilirubin <1.5x ULN; ALT and AST <1.5x ULN
Adequate organ and bone marrow functions: Absolute neutrophil count≥1.5x10^9/L; Platelet count≥100x10^9/L; Hemoglobin≥9g/dL; Serum bilirubin<1.5x ULN; ALT and AST<1.5x ULN; Serum creatinine<1.5x ULN; Endogenous creatinine clearance rate ≥ 50ml / min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify